Biosimilarity

Discover the intricacies of biosimilar drug approval in the United States with Biosimilarity by Sarfaraz K. Niazi. Published by Taylor & Francis Inc in 2018, this comprehensive hardback edition spans 398 pages, providing in-depth insights into the regulatory landscape governed by the FDA. While Europe has established specific guidelines for biosimilar approval, this book delves into the unique considerations and approaches taken by the FDA, offering a critical analysis of the approval process. Ideal for professionals in the pharmaceutical and regulatory fields, Biosimilarity serves as an essential resource for understanding the complexities of price regulation and the administrative frameworks that shape the future of biosimilars in the United States. Enhance your knowledge and stay informed about the evolving landscape of drug approval with this authoritative guide.